Brian Bradbury
Dr. Brian Bradbury is Vice President and Head of the Center for Observational Research (CfOR) at Amgen Inc. He leads a global team of epidemiologists, data scientists, programmers and operations professionals who generate real-world evidence (RWE) to support Amgen’s medicines across the drug development lifecycle. His team collaborates with stakeholders across the healthcare ecosystem to advance the use of high-quality RWE to help inform decision-making and to help achieve Amgen’s mission to serve patients. Brian holds an Adjunct Professor of Epidemiology appointment at the University of California, Los Angeles. He received his DSc in Epidemiology from Boston University (2004) and has authored/co-authored 90+ peer-reviewed publications in the areas of pharmacoepidemiology, bone, cancer and kidney disease epidemiology, and methods for controlling confounding in comparative effectiveness and safety studies.
Education
- DSc, Epidemiology, Boston University School of Public Health, Boston, MA
- MA, Education and Psychology, Pepperdine University Graduate School of Education & Psychology, Malibu, CA
Areas of Interest
Dr. Bradbury's current research interests include better characterizing the clinical course and consequences of anemia and secondary hyperparathyroidism in patients with chronic kidney disease; methods for conducting post-marketing drug surveillance studies; longitudinal data analysis using large databases; and application of methods for controlling time-dependent confounding and confounding-by-indication in studies of treatment effects.
Selected Publications
- Kilpatrick Ryan D, Gilbertson Dave, Brookhart M Alan, Polley Eric, Rothman Kenneth J, Bradbury Brian D Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions.. Pharmacoepidemiology and drug safety. 2012; 125(9):
- Brookhart M Alan, Bradbury Brian D, Avorn Jerry, Schneeweiss Sebastian, Winkelmayer Wolfgang C The effect of altitude change on anemia treatment response in hemodialysis patients.. American journal of epidemiology. 2011; 173(7): 768-77.
- Ng Leslie J, Chen Fangfei, Pisoni Ronald L, Krishnan Mahesh, Mapes Donna, Keen Marcia, Bradbury Brian D Hospitalization risks related to vascular access type among incident US hemodialysis patients.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011; 173(7).
- Weinhandl Eric D, Peng Yi, Gilbertson David T, Bradbury Brian D, Collins Allan J Hemoglobin variability and mortality: confounding by disease severity.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2011; 57(2): 255-65.
- Brookhart M Alan, Schneeweiss Sebastian, Avorn Jerry, Bradbury Brian D, Liu Jun, Winkelmayer Wolfgang C Comparative mortality risk of anemia management practices in incident hemodialysis patients.. JAMA : the journal of the American Medical Association. 2010; 303(9): 857-64.
- Bradbury Brian D, Brookhart M Alan, Winkelmayer Wolfgang C, Critchlow Cathy W, Kilpatrick Ryan D, Joffe Marshall M, Feldman Harold I, Acquavella John F, Wang Ouhong, Rothman Kenneth J Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2009; 54(3): 554-60.